本页面由Tiger Trade Technology Pte. Ltd.提供服务

Vir Biotechnology, Inc.

11.30
-0.4000-3.42%
盘后:11.20-0.1000-0.88%17:28 EDT
成交量:108.62万
成交额:1,235.26万
市值:19.06亿
市盈率:-6.66
高:11.82
开:11.63
低:11.21
收:11.70
52周最高:12.00
52周最低:4.82
股本:1.69亿
流通股本:1.30亿
量比:0.38
换手率:0.84%
股息:- -
股息率:- -
每股收益(TTM):-1.6972
每股收益(LYR):-3.1619
净资产收益率:-26.08%
总资产收益率:-14.51%
市净率:1.94
市盈率(LYR):-3.57

数据加载中...

2026/04/30

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2026/04/29

超过5%披露

Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors
2026/04/10

重要事件披露

Form 8-K - Current report
2026/04/06

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2026/03/23

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2026/03/04

重要事件披露

Form 8-K - Current report
2026/03/03

关联方拟减持公告

Form 144 | VIR BIO高管 Vicki Lee Sato 拟减持88000股,总价约80万美元
2026/03/02

重要事件披露

Form 8-K - Current report
2026/02/26

重要事件披露

Form 8-K - Current report
2026/02/25

关联方拟减持公告

Form 144 | Vir Biotechnology 股东 SVF Endurance (Cayman) Limited 拟减持40万股,总价约380万美元
2026/02/25

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2026/02/25

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2026/02/24

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2026/02/24

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2026/02/24

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2026/02/24

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2026/02/24

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2026/02/24

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2026/02/23

员工持股计划

Form S-8 - Securities to be offered to employees in employee benefit plans
2026/02/23

年度报告

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]